(Q47944468)

English

Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study

scientific article published on 21 January 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

0 references

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum to: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.

0 references

Cornelia von Hagens

object named as

Cornelia von Hagens

2

0 references

author name string

Miriam König

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

Sebastian Hoth

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

Ingo Baumann

4

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

Ingeborg Walter-Sack

5

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

Lutz Edler

6

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

Serkan Sertel

7

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

publication date

21 January 2016

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

77

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

413-427

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Antimalarial dihydroartemisinin also inhibits angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Dose-dependent brainstem neuropathology following repeated arteether administration in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Comment on: Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Comment on: Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Toxic brainstem encephalopathy after artemisinin treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Factors determining sensitivity or resistance of tumor cell lines towards artesunate.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Artemisinins: their growing importance in medicine

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Anticancer activities of artemisinin and its bioactive derivatives

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Murine malaria is associated with significant hearing impairment

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Reversible audiometric threshold changes in children with uncomplicated malaria

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2960-7

21 January 2018

Identifiers

10.1007/S00280-016-2960-7

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/26793976

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47944468&oldid=2208965028"